Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity

J Allergy Clin Immunol. 2016 Jan;137(1):314-318.e5. doi: 10.1016/j.jaci.2015.07.006. Epub 2015 Aug 20.

Authors

Anja Rabenhorst¹, Silke Leja¹, Juliana Schwaab², Manuela Gehring³, Anja Förster¹, Michel Arock⁴, Andreas Reiter², Ulrike Raap³, Karin Hartmann⁵

Affiliations

¹ Department of Dermatology, University of Cologne, Cologne, Germany.
² III. Medical Clinic, Hematology and Oncology, Medical University of Mannheim, Mannheim, Germany.
³ Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
⁴ Molecular Oncology and Pharmacology, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, Cachan, France.
⁵ Department of Dermatology, University of Cologne, Cologne, Germany; Department of Dermatology, University of Luebeck, Luebeck, Germany. Electronic address: karin.hartmann@uksh.de.

PMID: 26299988
DOI: 10.1016/j.jaci.2015.07.006

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
B7-H1 Antigen / blood*
Bone Marrow / immunology
Child
Child, Preschool
Female
Humans
Infant
Infant, Newborn
Male
Mastocytosis / blood*
Mastocytosis / immunology
Middle Aged
Programmed Cell Death 1 Ligand 2 Protein / blood*
Programmed Cell Death 1 Receptor / blood*
Severity of Illness Index
Skin / immunology
Tryptases / blood
Tryptases / immunology

Substances

B7-H1 Antigen
CD274 protein, human
PDCD1 protein, human
PDCD1LG2 protein, human
Programmed Cell Death 1 Ligand 2 Protein
Programmed Cell Death 1 Receptor
Tryptases